The Adult and Adolescent ARV Guidelines were updated on February 12, 2013.
Please send your comments with the subject line "Comments on Adult and Adolescent ARV Guidelines" to ContactUs@aidsinfo.nih.gov by February 26, 2013.
(Last updated:2/12/2013; last reviewed:2/12/2013)
Appendix B, Table 4. Characteristics of Integrase Inhibitors
Click here to view this table as an image
Generic Name (Abbreviation)/ Trade Name
(For dosage adjustment in hepatic insufficiency, see Appendix B, Table 7.)
Route of Metabolism
(Also see Table 13.)
800 mg BID
Take without regard to meals.
Not recommended for patients with baseline CrCl< 70 mL/min. See Appendix B Table 7 for the equation for calculating CrCl.
Not recommended for use with other antiretroviral drugs
COBI: CYP3A, CYP2D6 (minor)